Hyperbaric Chamber for Depression: What the Research Actually Shows

HBOT significantly reduced depression scores in post-stroke patients in a randomized sham-controlled trial, and a systematic review of 6 RCTs found consistent antidepressant effects across studies. The evidence is strongest when depression follows neurological injury. For primary major depression without a neurological trigger, the data is limited to small trials and animal models.

How HBOT May Help Depression

Depression is increasingly understood as more than a simple chemical imbalance. Research over the past two decades has revealed that neuroinflammation, impaired neuroplasticity, reduced cerebral blood flow, and mitochondrial dysfunction all play significant roles in depressive disorders. HBOT targets several of these pathways, which is why researchers have taken an interest in its potential.

Neuroinflammation Reduction

Chronic low-grade inflammation in the brain is strongly linked to depression. Elevated levels of pro-inflammatory cytokines such as IL-6, TNF-alpha, and CRP are consistently found in people with major depressive disorder. HBOT has been shown to reduce inflammatory markers in both animal models and human studies, potentially calming the neuroinflammatory processes that contribute to depressive symptoms.³

BDNF and Neuroplasticity

Brain-derived neurotrophic factor (BDNF) is a protein essential for the growth, survival, and repair of neurons. People with depression tend to have lower BDNF levels. Several studies have found that repeated HBOT sessions can increase BDNF expression, which may help restore the brain’s ability to form new neural connections and adapt to stress. A 2026 sham-controlled trial demonstrated that HBOT-driven BDNF increases correlated directly with reductions in depression scores (r=0.66).¹

In a randomized sham-controlled trial, HBOT significantly reduced depression scores in post-stroke patients at both 2 and 4 weeks, with improvements correlated to increased brain-derived neurotrophic factor (BDNF) levels.

Tang et al., Neuropsychiatric Disease and Treatment, 2026

Cerebral Blood Flow

Neuroimaging research has identified reduced blood flow in specific brain regions among people with depression, particularly the prefrontal cortex. HBOT delivers oxygen at higher-than-normal pressures, which can improve perfusion in oxygen-deprived brain tissue and potentially restore function in underperforming areas.

Mitochondrial Function

Mitochondria are the energy producers of every cell, and there is growing evidence that mitochondrial dysfunction contributes to depression. When brain cells cannot produce sufficient energy, cognitive function, mood regulation, and stress resilience all suffer. HBOT provides a surplus of dissolved oxygen that may support mitochondrial repair and improve cellular energy production in the brain.

Research Evidence

It is important to be transparent about where the science stands. The research on HBOT for depression is promising but limited. Here is what we know so far.

Animal Studies

Multiple animal studies have demonstrated antidepressant-like effects from hyperbaric oxygen exposure. Rodent models of depression have shown reduced depressive behaviors, lower inflammatory markers, and increased BDNF levels following HBOT protocols. While animal data cannot be directly applied to humans, these studies provide a biological rationale for further investigation.³

Human Clinical Trials

A 2026 randomized sham-controlled trial by Tang et al. enrolled 61 patients with post-stroke depression (29 HBOT, 32 sham) in a double-blind design. HBOT produced significantly lower HAMD scores than sham at week 2 (P=0.017) and week 4 (P<0.001), with concurrent elevations in serum BDNF and beta-NGF (P<0.01).¹

A systematic review of 6 randomized controlled trials published in 2026 found that HBOT consistently reduced depressive symptoms and improved cognitive and functional outcomes across studies. Combining HBOT with pharmacological treatments showed rapid improvements across psychological, neurological, and cognitive measures.²

A 2025 double-blind randomized controlled trial in adults with persistent post-brain-injury symptoms found that 40 HBOT sessions produced greater symptom reduction than sham (mean difference 7.0, 95% CI 1.7-12.3, P=0.01), with improvements across cognitive, affective, and somatic domains. An additional 40 sessions produced further gains.⁴

A systematic review of 6 randomized trials found HBOT consistently reduced depressive symptoms and improved cognitive and functional outcomes, including when combined with standard antidepressant medications.

Ahsan et al., 2026

What Is Still Missing

The honest assessment is that we do not yet have large-scale, multi-center RCTs specifically focused on HBOT for depression as a primary condition. Most studies to date have been small, and many involved patients whose depression was secondary to another condition such as TBI or chronic pain. The field needs larger trials with standardized protocols before HBOT can be recommended as a depression treatment with the same confidence as established therapies. For a broader look at the current state of the science, see our HBOT research overview.

HBOT vs. Traditional Depression Treatments

Standard treatments for depression include psychotherapy (particularly cognitive behavioral therapy), antidepressant medications such as SSRIs and SNRIs, exercise, and lifestyle interventions. These approaches are backed by decades of research and remain the foundation of depression care. HBOT is not a replacement for any of these. No responsible practitioner should suggest discontinuing medication or therapy in favor of HBOT. Instead, the most realistic role for HBOT is as a complementary approach, used alongside conventional treatment, particularly for individuals who have not responded adequately to first-line options.

Some parallels can be drawn to other adjunctive treatments that have gained acceptance in recent years, such as ketamine infusions and transcranial magnetic stimulation (TMS). Both started with limited evidence and gradually earned broader recognition as more data accumulated. HBOT may follow a similar trajectory, but it is not there yet.

If you are interested in how HBOT fits within the broader picture of mental health applications, our guide to hyperbaric oxygen therapy for mental health covers the full landscape. You may also want to read about HBOT for PTSD, which has a more established body of research.

Treatment Protocols for Depression

There is no universally agreed-upon HBOT protocol for depression, since the research is still evolving. However, the studies that have shown positive results generally share some common parameters. You can learn more in our what to expect during treatment guide.

• Pressure: Most protocols use 1.5 to 2.0 ATA (atmospheres absolute). Some researchers favor the lower end of this range for neurological conditions, as excessive pressure is not necessarily more effective for brain-related applications.
• Session duration: Typically 60 to 90 minutes of oxygen breathing time per session.
• Frequency: Five sessions per week is the most common schedule in clinical studies.
• Total sessions: Studies have used anywhere from 20 to 60 total sessions. A course of 30 to 40 sessions is a reasonable starting point based on available data.

Because protocols are not standardized, anyone pursuing HBOT for depression should work with a provider experienced in neurological applications and maintain realistic expectations about timelines. Results in studies were typically measured after the full course of treatment, not after a handful of sessions.

Who Might Benefit Most

Based on the existing evidence, certain groups may be more likely to see benefit from HBOT as an adjunctive depression treatment.

Treatment-Resistant Depression

Roughly 30% of people with major depressive disorder do not achieve full remission with standard antidepressants and therapy. For this group, adding novel interventions such as HBOT may be worth exploring, especially given its relatively favorable safety profile.

Depression Co-Occurring with TBI or Stroke

The strongest evidence for HBOT’s effect on depression comes from post-stroke and post-TBI populations. Depression is extremely common after brain injuries, and studies suggest HBOT may address both the structural brain damage and the accompanying mood symptoms simultaneously.¹

Evidence for HBOT in depression is strongest when depression is secondary to neurological injury. For primary major depression, data are more limited and require further investigation.

Depression Linked to Chronic Illness

Conditions associated with chronic inflammation and fatigue, such as Lyme disease, fibromyalgia, long COVID, and autoimmune disorders, frequently involve depression as a major component. Since HBOT targets inflammation and oxygenation at a systemic level, it may provide broader relief in these contexts.

Who Should Be Cautious

HBOT is generally well-tolerated, but it is not risk-free. People with certain lung conditions, untreated pneumothorax, or specific ear and sinus issues may not be candidates. Anyone considering HBOT should review the potential side effects of hyperbaric oxygen therapy and consult with both their mental health provider and the HBOT clinic before starting treatment.

Who Should Not Try HBOT

HBOT is generally safe when administered by trained professionals, but it is not appropriate for everyone. Discuss your full medical history with your provider before starting treatment.

Absolute Contraindications

HBOT should not be used if you have:

• Untreated pneumothorax (collapsed lung) – pressure changes can worsen this condition and become life-threatening
• Certain chemotherapy drugs – bleomycin, cisplatin, doxorubicin, and disulfiram may interact dangerously with high-oxygen environments

Relative Contraindications

Your provider may need to take extra precautions or postpone treatment if you have:

• Upper respiratory infection or sinus congestion – difficulty equalizing pressure can cause ear or sinus barotrauma
• Seizure disorder – high-pressure oxygen can lower seizure threshold in susceptible individuals
• Chronic obstructive pulmonary disease (COPD) – altered breathing drive may require modified protocols
• High fever – increases the risk of oxygen toxicity
• History of ear surgery or chronic ear problems – pressure equalization may be difficult or risky
• Claustrophobia – may require sedation or use of a multiplace chamber instead
• Pregnancy – insufficient safety data exists for routine use during pregnancy

Talk to Your Doctor First

Even if you do not have the conditions listed above, always consult your physician before starting HBOT, especially if you take insulin (blood sugar may drop during treatment), have a pacemaker or implanted device, or are currently taking any medications. For a full overview of HBOT side effects and risks, see our detailed guide.